Voronoi Receives Approval to Expand VRN11 Phase 1/2 Trial in Australia... Launches Clinical Trial in EGFR-Naive Patients in an Advanced Market
2026.05.28
Voronoi (310210) is accelerating the global clinical expansion of 'VRN11,' its next-generation EGFR targeted therapy.
Voronoi announced on the 28th that it recently obtained approval from Australia's Human Research Ethics Committee (HREC) for an amendment to its Phase 1/2 clinical trial protocol. With this approval, treatment-naïve patients with EGFR mutation non-small cell lung cancer (NSCLC) are now included in the trial population.
Currently, in the first-line EGFR mutation lung cancer market in advanced countries, AstraZeneca's third-generation EGFR inhibitor Tagrisso has effectively established itself as the standard of care. Against this backdrop, given that clinical trials targeting EGFR mutation lung cancer naive (first-line) patients in advanced countries have been rare since the advent of Tagrisso, the industry views this approval as more than a simple clinical expansion, seeing it as a signal that competition among next-generation EGFR therapies is beginning in earnest.
This trial is a global multicenter Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor effect of VRN11 in patients with advanced non-small cell lung cancer harboring EGFR mutations. It will be conducted in multiple regions including North America, Asia, Oceania, and Europe, with a target enrollment of approximately 391 patients.
According to the company, VRN11 at the 320 mg dose has demonstrated approximately four times higher target engagement than Tagrisso at 80 mg, and on this basis a more potent tumor-suppressing effect is expected.
Market attention is focused in particular on VRN11's CNS (central nervous system) penetration. EGFR lung cancer is known to be a cancer type with a high rate of brain metastasis, so CNS activity is regarded as a key factor that determines a therapy's competitiveness.
A Voronoi representative said, "Clinical data have confirmed VRN11's BBB (blood-brain barrier) penetration at approximately 200%. This is far higher than the roughly 20% of the existing standard therapy Tagrisso, and we expect it to secure differentiated competitiveness in patients with brain metastases going forward."
With this Australian approval, Voronoi expects to be able to begin Phase 1b/2 dosing in EGFR mutation lung cancer naive patients within the first half of the year. The industry is watching for early clinical efficacy data as well as whether CNS activity and brain metastasis patient data will be secured.
Voronoi announced on the 28th that it recently obtained approval from Australia's Human Research Ethics Committee (HREC) for an amendment to its Phase 1/2 clinical trial protocol. With this approval, treatment-naïve patients with EGFR mutation non-small cell lung cancer (NSCLC) are now included in the trial population.
Currently, in the first-line EGFR mutation lung cancer market in advanced countries, AstraZeneca's third-generation EGFR inhibitor Tagrisso has effectively established itself as the standard of care. Against this backdrop, given that clinical trials targeting EGFR mutation lung cancer naive (first-line) patients in advanced countries have been rare since the advent of Tagrisso, the industry views this approval as more than a simple clinical expansion, seeing it as a signal that competition among next-generation EGFR therapies is beginning in earnest.
This trial is a global multicenter Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor effect of VRN11 in patients with advanced non-small cell lung cancer harboring EGFR mutations. It will be conducted in multiple regions including North America, Asia, Oceania, and Europe, with a target enrollment of approximately 391 patients.
According to the company, VRN11 at the 320 mg dose has demonstrated approximately four times higher target engagement than Tagrisso at 80 mg, and on this basis a more potent tumor-suppressing effect is expected.
Market attention is focused in particular on VRN11's CNS (central nervous system) penetration. EGFR lung cancer is known to be a cancer type with a high rate of brain metastasis, so CNS activity is regarded as a key factor that determines a therapy's competitiveness.
A Voronoi representative said, "Clinical data have confirmed VRN11's BBB (blood-brain barrier) penetration at approximately 200%. This is far higher than the roughly 20% of the existing standard therapy Tagrisso, and we expect it to secure differentiated competitiveness in patients with brain metastases going forward."
With this Australian approval, Voronoi expects to be able to begin Phase 1b/2 dosing in EGFR mutation lung cancer naive patients within the first half of the year. The industry is watching for early clinical efficacy data as well as whether CNS activity and brain metastasis patient data will be secured.